Satyanarayana Chava – CEO, Laurus Labs, India

Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well as the partner of choice of the most prominent MNCs globally - after only 13 years of existence. He also outlines his expectations for the development of the company's formulations and CDMO businesses, which follows Chava’s vision to establish Laurus as a leading player in offering integrated solutions for global pharmaceutical needs.  Having previously worked for large domestic companies such as Ranbaxy and Matrix Labs, you founded Laurus Labs in 2005. Since then the company has achieved impressive results with revenues of over USD 280 million, while it also services nine out of the ten largest generics companies in the world. What have been the main fundamentals behind this success story?
"In the grand scheme of things, our strategy is to gain a dominant position in a few, well-identified product categories rather than building a huge product portfolio. In the meantime, we want to increase our presence across the globe."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report